About: T. Scott Stroup

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: T. Scott Stroup Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher ORCID ID = 0000-0002-3123-0672

Attributes	Values
rdf:type	Item
description	forskare (sv) 연구원 (ko) 研究者 (ja) araştırmacı (tr) эрдэмтэн (mn) वैज्ञानिक (hi) изилдөөчү (ky) onderzoeker (nl) researcher ORCID ID = 0000-0002-3123-0672 (en)
rdfs:label	Scott Stroup (es) Scott Stroup (nl) Scott Stroup (ast) T. Scott Stroup (en)
skos:prefLabel	Scott Stroup (es) Scott Stroup (nl) Scott Stroup (ast) T. Scott Stroup (en)
name	Scott Stroup (es) Scott Stroup (nl) Scott Stroup (ast) T. Scott Stroup (en)
Scopus author ID	wds:Q59149894-EEBF64E4-B781-4017-9BF3-F4631595E635
Scopus author ID	6701317476
given name	wds:Q59149894-2D5239ED-8A9F-4D6F-B29C-B5E81FD05AC0
given name	Scott
instance of	wds:Q59149894-6D1BD3E4-4617-4E64-BF93-217F39B532E3
instance of	Homo sapiens
skos:altLabel	Scott Stroup (en) Thomas S. Stroup (en) Thomas Stroup (en)
occupation	wds:Q59149894-4978FE42-F107-41BC-B427-84F9F6BF36F5
NUKAT ID	wds:Q59149894-3E597BB8-2EA2-4B7D-9D0E-6B70FA1DFF6D
sex or gender	wds:Q59149894-320c750f-4db8-c7d6-4f29-7e84068d63ed
ISNI	wds:Q59149894-24BC4FA9-C74B-4F96-94AC-9B87743760DC
VIAF ID	wds:Q59149894-3f0b56c9-4ed7-04e3-eba5-d67314bf3ef9
GND ID	wds:Q59149894-509e1c33-47cd-f43a-30e4-343387d89132
IdRef ID	wds:Q59149894-9C4CFD5D-3C05-4F20-8550-6AA1C96569B9
date of birth	wds:Q59149894-7F791655-2237-44D7-9251-AF10C9FFEB8F
National Library of Israel J9U ID	wds:Q59149894-5CFAEC52-E647-4ABF-9E35-A48DED676CB9
VIAF ID	http://viaf.org/viaf/41258591
GND ID	https://d-nb.info/gnd/143271393
IdRef ID	http://www.idref.fr/108432068/id
occupation	researcher
NUKAT ID	n2006146459
sex or gender	male
ISNI	0000000114711100
VIAF ID	41258591
GND ID	143271393
IdRef ID	108432068
date of birth	1960-01-01 00:00:00Z (xsd:dateTime)
National Library of Israel J9U ID	987007440565905171
ORCID iD	wds:Q59149894-B55299E7-31A7-48EC-A2A7-9218F13A580D
ORCID iD	https://orcid.org/0000-0002-3123-0672
ORCID iD	0000-0002-3123-0672
ResearcherID	wds:Q59149894-2674891E-E935-41AE-B775-CB20646054C3
ResearcherID	F-9188-2014
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q59149894
is author of	Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Microduplications of 16p11.2 are associated with schizophrenia Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Effectiveness of switching antipsychotic medications Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial Effectiveness of antipsychotic drugs in patients with chronic schizophrenia Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) Pragmatic design in randomized controlled trials. What can large simple trials do for psychiatry? The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Genomewide association for schizophrenia in the CATIE study: results of stage 1 Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Genomewide association study of movement-related adverse antipsychotic effects NCAM1 and neurocognition in schizophrenia Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. The NIMH-CATIE Schizophrenia Study: what did we learn? Sexually dimorphic aging of dendritic morphology in CA1 of hippocampus. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software